Soligenix, Inc.

DB:DOA Stock Report

Market Cap: €7.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Soligenix Management

Management criteria checks 2/4

Soligenix's CEO is Christopher Schaber, appointed in Aug 2006, has a tenure of 16.75 years. total yearly compensation is $711.19K, comprised of 70.2% salary and 29.8% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth €16.11K. The average tenure of the management team and the board of directors is 8.9 years and 13.9 years respectively.

Key information

Christopher Schaber

Chief executive officer

US$711.2k

Total compensation

CEO salary percentage70.23%
CEO tenure16.8yrs
CEO ownership0.2%
Management average tenure8.9yrs
Board average tenure13.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Christopher Schaber's remuneration changed compared to Soligenix's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2022US$711kUS$499k

-US$14m

Sep 30 2022n/an/a

-US$15m

Jun 30 2022n/an/a

-US$15m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$687kUS$485k

-US$13m

Sep 30 2021n/an/a

-US$13m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$12m

Dec 31 2020US$944kUS$475k

-US$18m

Sep 30 2020n/an/a

-US$15m

Jun 30 2020n/an/a

-US$16m

Mar 31 2020n/an/a

-US$15m

Dec 31 2019US$688kUS$466k

-US$9m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$619kUS$453k

-US$9m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$7m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$674kUS$444k

-US$7m

Sep 30 2017n/an/a

-US$5m

Jun 30 2017n/an/a

-US$6m

Mar 31 2017n/an/a

-US$4m

Dec 31 2016US$598kUS$435k

-US$3m

Compensation vs Market: Christopher's total compensation ($USD711.19K) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Christopher's compensation has increased whilst the company is unprofitable.

CEO

Christopher Schaber (56 yo)

16.8yrs
Tenure
US$711,186
Compensation

Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Schaber
Chairman of the Board of Directors16.8yrsUS$711.19k0.20%
€ 16.1k
Jonathan Guarino
Senior VP3.7yrsUS$355.35k0.025%
€ 2.0k
Oreola Donini
Senior VP & Chief Scientific Officer8.4yrsUS$364.24k0%
€ 0
Richard Straube
Senior VP & Chief Medical Officer9.3yrsUS$242.33k0.018%
€ 1.4k
8.9yrs
Average Tenure
53yo
Average Age

Experienced Management: DOA's management team is seasoned and experienced (8.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Schaber
Chairman of the Board of Directors16.8yrsUS$711.19k0.20%
€ 16.1k
Jerome Zeldis
Independent Director11.9yrsUS$80.00k0.052%
€ 4.1k
Gregory Lapointe
Independent Director14.2yrsUS$87.50k0.017%
€ 1.3k
Robert Rubin
Independent Director13.6yrsUS$85.00k0.010%
€ 785.2
Dorothy Mary Keefe
Member of Oral Mucositis Medical Advisory Boardno datano datano data
Jeffrey Hyams
Member of Pediatric Crohn's Disease Medical Advisory Boardno datano datano data
James Markowitz
Member of Pediatric Crohn's Disease Medical Advisory Boardno datano datano data
Joel Rosh
Member of Pediatric Crohn's Disease Medical Advisory Boardno datano datano data
Alain Rook
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno datano datano data
Mark Schubert
Member of Oral Mucositis Medical Advisory Boardno datano datano data
Youn Kim
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno datano datano data
Gary Wood
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno datano datano data
13.9yrs
Average Tenure
67.5yo
Average Age

Experienced Board: DOA's board of directors are seasoned and experienced ( 13.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/05/09 17:02
End of Day Share Price 2023/02/09 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Soligenix, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Andrew D'SilvaB. Riley Securities, Inc.
Keith MarkeyGriffin Securities